

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

Predictmedix Inc. (formerly Cultivar Holdings Inc.)
3000 - 77 King Street West
Toronto, Ontario M5K 1G8

Item 2. Date of Material Change

April 9, 2020

Item 3. News Releases

A press release in the form of Schedule A attached hereto was disseminated on April 9, 2020 via The Newswire and subsequently filed on the System for Electronic Document Analysis and Retrieval (www.sedar.com).

Item 4. Summary of Material Change

Predictmedix Inc. (CSE: PMED) (OTCQB: PMEDF) (formerly Cultivar Holdings Inc.) (the "Company") has announced that it has completed its name change from "Cultivar Holdings Inc." to "Predictmedix Inc." (the "Name Change"). The articles of the Company provide the directors with the authority to change the name of the Company by way of directors resolution without consent of the shareholders. Common shares owned by shareholders of the Company will automatically be adjusted as a result of the Name Change and no further action is required to be taken by shareholders.

In connection with the Name Change, the Company's trading symbol, as listed on the CSE and the OTCQB have also been changed from "CULT" to "PMED", and from "CVRHF" to "PMEDF", respectively.

Item 5. Full Description of Material Change

5.1 Full Description of Material Change

See Schedule A attached.

5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

Not applicable.

Item 8. Executive Officer

The following officer of the Company may be contacted for further information:

Rahul Kushwah, Chief Operating Officer

Tel: 647 889-6916

Email: Rahul.kushwahphd@gmail.com

Item 9. Date of Report

This report is dated this 9th day of April, 2020.

SCHEDULE A

CULTIVAR HOLDINGS INC. ANNOUNCES ITS NAME CHANGE TO PREDICTMEDIX INC.

Toronto, Ontario - (April 9, 2020) – Predictmedix Inc. (CSE: PMED) (OTCQB: PMEDF) (formerly Cultivar Holdings Inc.) (the "Company") is pleased to announce that it has completed its name change from "Cultivar Holdings Inc." to "Predictmedix Inc." (the "Name Change"). The articles of the Company provide the directors with the authority to change the name of the Company by way of directors resolution without consent of the shareholders. Common shares owned by shareholders of the Company will automatically be adjusted as a result of the Name Change and no further action is required to be taken by shareholders. The CUSIP number assigned to the Company's common shares following the name change is: CUSIP 74040L100 (ISIN CA74040L1004).

In connection with the Name Change, the Company's trading symbol, as listed on the CSE and the OTCQB have also been changed from "CULT" to "PMED", and from "CVRHF" to "PMEDF", respectively.

The Company has also retained the services of the well-respected British Columbia corporate communications company, MarketSmart Communications Inc. ("MarketSmart"). MarketSmart will help the Company develop and implement a strategic corporate communications program to increase its visibility and exposure among industry stakeholders and investors across Canada and U.S. In connection with the engagement, the Company has agreed to pay MarketSmart a monthly fee of \$6,000 (plus GST) for six (6) months, and has granted options to purchase up to 200,000 Company common shares at \$0.15 per share for a period of twelve (12) months from the issue date. The options will immediately vest upon issuance.

About Predictmedix Inc.

Predictmedix Inc. is an artificial intelligence ("AI") company developing disruptive and cutting-edge tools for impairment testing and healthcare. It is intended that the Company's cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice. The Company has partnered with Tech Mahindra and Hindalco to help expedite the launch of its impairment technology, as well as the prestigious Indian Institute of Technology.

The Company is also developing cutting edge screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious diseases such as influenza and coronaviruses (COVID-19). Additionally, psychiatric disorders such as depression, dementia and Alzheimer's disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer's disease.

For further information, please contact:

Rahul Kushwah, Chief Operating Officer

Tel: 647 889-6916

Email: Rahul.kushwahphd@gmail.com

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.